51 related articles for article (PubMed ID: 36422490)
21. Real-world effectiveness of fulvestrant monotherapy as first endocrine treatment in patients with metastatic breast cancer.
Skinner KE; Olufade T; Walker MS; Schwartzberg LS
Breast J; 2020 Feb; 26(2):112-119. PubMed ID: 31531938
[TBL] [Abstract][Full Text] [Related]
22. Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience.
Palumbo R; Sottotetti F; Quaquarini E; Gambaro A; Ferzi A; Tagliaferri B; Teragni C; Licata L; Serra F; Lapidari P; Bernardo A
Ther Adv Med Oncol; 2019; 11():1758835919833864. PubMed ID: 31210797
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK.
Telford C; Bertranou E; Large S; Phelps H; Ekman M; Livings C
Pharmacoecon Open; 2019 Dec; 3(4):559-570. PubMed ID: 31025302
[TBL] [Abstract][Full Text] [Related]
24. Real-world data: towards achieving the achievable in cancer care.
Booth CM; Karim S; Mackillop WJ
Nat Rev Clin Oncol; 2019 May; 16(5):312-325. PubMed ID: 30700859
[TBL] [Abstract][Full Text] [Related]
25. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Bray F; Ferlay J; Soerjomataram I; Siegel RL; Torre LA; Jemal A
CA Cancer J Clin; 2018 Nov; 68(6):394-424. PubMed ID: 30207593
[TBL] [Abstract][Full Text] [Related]
26. Trends in breast cancer mortality by stage at diagnosis among young women in the United States.
Guo F; Kuo YF; Shih YCT; Giordano SH; Berenson AB
Cancer; 2018 Sep; 124(17):3500-3509. PubMed ID: 30189117
[TBL] [Abstract][Full Text] [Related]
27. Recent Advances in the Treatment of Breast Cancer.
Tong CWS; Wu M; Cho WCS; To KKW
Front Oncol; 2018; 8():227. PubMed ID: 29963498
[TBL] [Abstract][Full Text] [Related]
28. Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting.
Pizzuti L; Natoli C; Gamucci T; Mauri M; Sergi D; Di Lauro L; Paoletti G; Ruggeri E; Iezzi L; Sperduti I; Mentuccia L; Fabbri A; Maugeri-Saccà M; Moscetti L; Barba M; Vici P
Oncotarget; 2017 Sep; 8(40):69025-69037. PubMed ID: 28978178
[TBL] [Abstract][Full Text] [Related]
29. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Robertson JFR; Bondarenko IM; Trishkina E; Dvorkin M; Panasci L; Manikhas A; Shparyk Y; Cardona-Huerta S; Cheung KL; Philco-Salas MJ; Ruiz-Borrego M; Shao Z; Noguchi S; Rowbottom J; Stuart M; Grinsted LM; Fazal M; Ellis MJ
Lancet; 2016 Dec; 388(10063):2997-3005. PubMed ID: 27908454
[TBL] [Abstract][Full Text] [Related]
30. Clinical predictors of benefit from fulvestrant in advanced breast cancer: A Meta-analysis of randomized controlled trials.
Graham J; Pitz M; Gordon V; Grenier D; Amir E; Niraula S
Cancer Treat Rev; 2016 Apr; 45():1-6. PubMed ID: 26922660
[TBL] [Abstract][Full Text] [Related]
31. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.
Montemurro F; Di Cosimo S; Arpino G
Ann Oncol; 2013 Nov; 24(11):2715-24. PubMed ID: 23908178
[TBL] [Abstract][Full Text] [Related]
32. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.
Huober J; Fasching PA; Barsoum M; Petruzelka L; Wallwiener D; Thomssen C; Reimer T; Paepke S; Azim HA; Ragosch V; Kubista E; Baumgärtner AK; Beckmann MW; May C; Nimmrich I; Harbeck N
Breast; 2012 Feb; 21(1):27-33. PubMed ID: 21862331
[TBL] [Abstract][Full Text] [Related]
33. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
Di Leo A; Jerusalem G; Petruzelka L; Torres R; Bondarenko IN; Khasanov R; Verhoeven D; Pedrini JL; Smirnova I; Lichinitser MR; Pendergrass K; Garnett S; Lindemann JP; Sapunar F; Martin M
J Clin Oncol; 2010 Oct; 28(30):4594-600. PubMed ID: 20855825
[TBL] [Abstract][Full Text] [Related]
34. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.
Schwartzberg LS; Franco SX; Florance A; O'Rourke L; Maltzman J; Johnston S
Oncologist; 2010; 15(2):122-9. PubMed ID: 20156908
[TBL] [Abstract][Full Text] [Related]
35. Activity of fulvestrant in HER2-overexpressing advanced breast cancer.
Robertson JFR; Steger GG; Neven P; Barni S; Gieseking F; Nolè F; Pritchard KI; O'Malley FP; Simon SD; Kaufman B; Petruzelka L
Ann Oncol; 2010 Jun; 21(6):1246-1253. PubMed ID: 19875750
[TBL] [Abstract][Full Text] [Related]
36. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Kaufman B; Mackey JR; Clemens MR; Bapsy PP; Vaid A; Wardley A; Tjulandin S; Jahn M; Lehle M; Feyereislova A; Révil C; Jones A
J Clin Oncol; 2009 Nov; 27(33):5529-37. PubMed ID: 19786670
[TBL] [Abstract][Full Text] [Related]
37. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
38. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.
De Laurentiis M; Arpino G; Massarelli E; Ruggiero A; Carlomagno C; Ciardiello F; Tortora G; D'Agostino D; Caputo F; Cancello G; Montagna E; Malorni L; Zinno L; Lauria R; Bianco AR; De Placido S
Clin Cancer Res; 2005 Jul; 11(13):4741-8. PubMed ID: 16000569
[TBL] [Abstract][Full Text] [Related]
39. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.
Osborne CK; Wakeling A; Nicholson RI
Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S2-6. PubMed ID: 15094757
[TBL] [Abstract][Full Text] [Related]
40. The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study.
Güven DC; Yıldırım HÇ; Erul E; Şahin TK; Çakır İY; Aktepe OH; Kertmen N; Dizdar Ö; Aksoy S
Turk J Med Sci; 2022 Oct; 52(5):1551-1558. PubMed ID: 36422490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
